This is a copy of the December 30th edition of our weekly Newsletter, which we have been publishing since October 2015.
Friends,
As we reach the end of 2018, we want to thank all our readers for relying on New Cannabis Ventures for their go-to source of high quality business news and financial content within the cannabis industry. Our readership broadly spans executives, financial institutions, family offices, municipalities and regulatory authorities, as well as big law, accountancy, advisory, analysts, academics, media journalists, entrepreneurs and retail investors alike who are all navigating this highly regulated but quite complex industry together.
We continue to serve our core vision and mission statement, which was written in late 2015 as this publication initially launched. Succinctly, being a reader of New Cannabis Ventures means you are at the forefront of the industries most important news, saving you immense time while keeping you on top of this rapidly-changing landscape, discovering companies, markets, trends and opportunities, before the majority of your peers. Consequently, our readers are also well informed about the many market risks and questionable companies that thrive in a new market with lots of distractions and noise. We believe that our continuous distribution of quality news, information and interviews has raised the bar for entities that vie for our readers attention.
For more than three years, New Cannabis Ventures readers have subscribed to a philosophy of quality over quantity, and thus, are shielded from low-grade news flow, most often distributed by unscrupulous market opportunists, and instead delivered quality financial and business news that meets both an internal qualitative and quantitative criteria. We are able to do this by having an advanced financial background to evaluate complex industry deals and news in real-time.
This year we introduced exclusive, hand-selected, interviews of CEOs of leading and up-and-coming cannabis companies and cannabis-focused investors. In all, we published 61 interviews, with summaries as well as the full audio, all with a goal of giving our readers a front row seat to the industry. New Cannabis Ventures often acts as the proverbial springboard for companies covered, and we note that 7 of these companies subsequently agreed to be acquired, including 4Front, ebbu, Emblem, Hiku Brands, MedReleaf, MPX Bioceuticals and PharmaCann. DeepCell Industries received a 10% strategic investment as well. We will continue to invest our time and efforts into finding the companies worth getting to know better.
Readers of New Cannabis Ventures also depend on important proprietary content and market data via a suite of resources constructed to give a better understanding of key drivers of industry growth and its financial performance. At the beginning of the year, we launched a set of five professionally managed stock indices, including the popularized Global Cannabis Stock Index and the Canadian Cannabis LP Index and its three sub-indexes based on stage of development of the licensed producer. In November, we added the new American Cannabis Operators Index, which allows readers to track multi-state operators separately. In Q4, we debuted the Cannabis Stock IPOs and New Issues Tracker to help savvy readers stay on top of new companies going public as well as the Cannabis Investor Earnings Conference Call Calendar to help guide our readers to what we think are the most important communications from a public company, the ever expanding list of quarterly calls. Finally, we introduced our Careers Page with a goal of identifying some of the largest companies expanding rapidly and allowing our readers to quickly navigate their robust employment offerings.
As we get prepared for the turn of the calendar year, we are quite excited about what we believe lies ahead. In Canada, we expect to see revenue ramp up among licensed producers and retailers and improved profitability. For many of the Canadian LPs, their focus will increase towards international opportunities. In the U.S., we aren’t expecting too much progress on the regulatory front at the federal level, but, importantly, in contrast to our concerns a year ago, we also don’t see headwinds. Status quo can be a great thing! In addition to multi-state operators continuing to ramp up sales organically, we expect to see more consolidation and more companies heading to the public markets as the need for capital increases as competition for market share increases. Additionally, Colorado, the most mature state-legal cannabis program, is very likely to allow public company ownership next year, and perhaps Michigan will as well. Finally, we anticipate several American ancillary public companies currently trading on the OTC to uplist to a major exchange and also further consolidation within the cannabis media landscape as the ownership of reputable distribution channels and the data and deal flow that comes with it becomes increasingly more valuable to various industries.
While the sharp decline in share prices late in the year was disheartening for many, we don’t believe that it reflects the tremendous growth and opportunities that lie ahead for our industry. New Cannabis Ventures is proud to have contributed toward a mandated philanthropic goal of 2% yearly revenue to industry non-profit groups that are working hard for responsible legalization and a favorable social, economic and legal environment for the industry. We are quite excited about the prospects for the cannabis industry in 2019, and we look forward to continuing to responsibly serve our readers and clients with our suite of services and much more in the future.
Join us at the the Benzinga Cannabis Capital Conference, the premier gathering of cannabis entrepreneurs and investors in North America on January 16th in Miami, FL. This will be a full day of engaging panels, exclusive investor presentations, and speed-networking. Make deals and learn from influencers, policymakers and trailblazers. Meet Alan and hundreds of other industry pioneers that can help expand your network. Upon selecting your ticket, use the check-out code “420ALAN“.
New Cannabis Ventures publishes curated articles as well as exclusive news. Here is some of the most interesting business content from this week:
- Exclusive: 13 Cannabis Stocks that Rallied in 2018
- Aphria Names Hain Celestial Founder as Independent Chair
- Green Growth Brands to Offer C$11 per Share in Stock for Aphria
- MedMen and PharmaCann Move Forward with Merger Plans
- Exclusive: Still Room for Improvement at the World’s First Cannabis ETF
- TerrAscend Enters U.S. Hemp Market with $13 Million Acquisition
- Exclusive: This Early MedMen Investor is Helping Institutional-Grade American Cannabis Companies Raise Capital
To get real-time updates download our free mobile app for Android or Apple devices, like our Facebook page, or follow Alan on Twitter. Share and discover industry news with like-minded people on the largest cannabis investor and entrepreneur group on LinkedIn.
Use the suite of professionally managed NCV Cannabis Stock Indices to monitor the performance of publicly-traded cannabis companies within the day or over longer time-frames. In addition to the comprehensive Global Cannabis Stock Index, we offer a family of indices to track Canadian licensed producers as well as the American Cannabis Operator Index.
View the Public Cannabis Company Revenue Tracker, which ranks the top revenue producing cannabis stocks that generate industry sales of more than $2.5m per quarter.
Discover upcoming new listings with the curated Cannabis Stock IPOs and New Issues Tracker.
Stay on top of some of the most important communications from public companies by viewing upcoming cannabis investor earnings conference calls.
Consider subscribing to 420 Investor, Alan’s comprehensive stock due diligence platform since 2013 for more in-depth information and market intelligence about the publicly traded cannabis sector.
Find your place in the cannabis industry by visiting our Careers and Jobs Page and learn which companies are hiring aggressively.
Sincerely,
Alan & Joel
